Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3820258 | 0.98 | TAAR1 (0.95) | TAAR1AOC3HRH3SIGMAR1MCHR1 | |
| SCHEMBL18762839 | 0.87 | HRH3 (0.84) | TAAR1AOC3HRH3SIGMAR1 | |
| SCHEMBL10677993 | 0.86 | TAAR1 (0.76) | TAAR1AOC3HRH3SIGMAR1 | |
| SCHEMBL11134095 | 0.85 | TAAR1 (0.73) | TAAR1AOC3HRH3SIGMAR1 | |
| SCHEMBL14790515 | 0.79 | TAAR1 (0.64) | TAAR1AOC3HRH3SIGMAR1MCHR1 | |
| SCHEMBL22882402 | 0.79 | TAAR1 (0.64) | TAAR1AOC3HRH3SIGMAR1MCHR1 | |
| SCHEMBL3046909 | 0.78 | HRH3 (0.70) | TAAR1HRH3 | |
| SCHEMBL1975214 | 0.78 | HRH3 (0.70) | TAAR1HRH3MCHR1 | |
| SCHEMBL3059072 | 0.78 | HRH3 (0.70) | TAAR1AOC3HRH3 | |
| SCHEMBL3057063 | 0.78 | HRH3 (0.70) | TAAR1AOC3HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-1453836-B1 | BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005093515-A1 | PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE FILM, AND PERMANENT PATTERN AND PROCESS FOR FORMING THE SAME | FUJI PHOTO FILM CO., LTD. (JP) | 2005-10-06 | — | — | WO | disclosed |
| EP-1177175-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068198-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-16 | — | — | WO | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | TAAR1 674/4885AOC3 415/4885HRH3 460/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | TAAR1 4519/4885AOC3 929/4885HRH3 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.